Biomarkers as Therapeutic Tools in Medical Diagnostics and Disease Monitoring

In the worldwide healthcare system, blood-based biomarkers for neurological illnesses have been recognized as important instruments for early diagnosis, disease monitoring, and individualized treatment. Currently, several research studies have reported robust assays of blood biomarkers for the identification of tau and beta-amyloid proteins for Alzheimer-type dementia. Neurofilament light polypeptide is linked to various conditions, including amyotrophic lateral sclerosis, and is used alongside inflammatory markers such as C-reactive protein and cytokines to assess neuroinflammation and underlying pathophysiologic processes. These biomarkers are intriguing, but they have issues related to standardization, sensitivity, and specificity. Blood-based biomarkers provide affordable, non-invasive diagnostic tools in the evolving healthcare landscape, particularly in resource-constrained countries where advanced imaging is less readily available. In the near future, blood-based biomarkers can be used for patient screening, tailored treatment, and remote care integration. Widespread acceptance, however, will depend on removing the present legislative and technological obstacles and guaranteeing consistent clinical utility. Blood-based biomarkers can be utilized for global management of neurological illnesses and have the potential to be used clinically. In this review, recent advancements and their fruitful implications, as discussed by neurologists, will be discussed. 

This narrative review examines contemporary predictive biomarkers and therapeutic interventions in the management of Inflammatory Bowel Disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). The literature was retrieved from databases including PubMed, Scopus, ScienceDirect, and Google Scholar using keywords such as “Inflammatory bowel disease,” “biomarkers,” and “therapeutic interventions,” with inclusion criteria focusing on peer-reviewed human studies published till 2025. The review critically examines conventional and emerging treatments, including antibiotics, TNF inhibitors, probiotics, prebiotics, microbial replacement therapy, nutritional interventions, immunomodulators, and cell adhesion molecule inhibitors. It also synthesizes current findings on predictive biomarkers, including microbial profiles, genetic polymorphisms, hematological indicators, immune mediators, fecal markers, and anti-drug antibodies, that influence therapeutic response. Major trends indicate a growing emphasis on personalized medicine through biomarker-guided therapy. However, challenges such as clinical variability, biomarker accessibility, and standardization remain. This review underscores the need for integrated, biomarker-based approaches to enhance treatment efficacy and patient outcomes in IBD.

This narrative review explores Parkinson's disease (PD), a progressive neurodegenerative condition that significantly affects motor function and is associated with significant neuroinflammatory processes. Activated microglia and astrocytes, along with the release of inflammatory mediators, trigger neuroinflammation, a crucial factor in the onset and progression of Parkinson's disease. Neuroinflammatory response biomarkers are important tools for understanding these pathways because they allow early diagnosis, tracking of disease progression, and judging how well a treatment is working. They are very important because they reveal factors like cytokines (TNF-α, IL-1β, and IL-6), markers of microglial activation (TSPO), signs of oxidative stress (nitric oxide and malondialdehyde), and complement system proteins (C3 and C4). Examining these biomarkers in cerebrospinal fluid and blood, along with modern imaging methods, simplifies the monitoring of inflammation levels in Parkinson's patients. This helps doctors determine the severity of the disease and identify areas for future treatment focus. Even though there are issues with biomarker specificity and repeatability, neuroinflammatory biomarker research is making progress. This can lead to better diagnosis, more personalized treatment plans, and a better understanding of how Parkinson's disease works at its core. This review synthesizes current knowledge on the categorization, functions, and prospective clinical applications of these biomarkers, concluding that they are crucial for enhancing diagnostic accuracy, enabling personalized treatment plans, and deepening the fundamental understanding of Parkinson's disease pathology.

 Several diseases can lead to life-threatening conditions, but their intermittent nature and vague symptoms often make diagnosis challenging. Therefore, activitybased diagnosis is an approach that simplifies the diagnostic process and improves accuracy. This narrative review examines the current scenario of activity-based diagnostic methods in infectious and non-infectious diseases, using various databases, including Google Scholar, PubMed, Web of Science, and Scopus (2000-2024). Clinical studies and review articles were included, with emphasis on technological advances and validation studies. The activity-based diagnosis has several advantages over traditional methods, like enhancing specificity, sensitivity, and detection time. The innovations include fluorescent probes, colorimetric detection systems, nanosensors, and the integration of artificial intelligence. Further clinical trial data show favorable results in cancer screening, as well asthe detection of infectious and chronic diseases, as this approach enhances targeted therapy and diagnosis.

Coronary artery disease (CAD) remains one of the major causes of morbidity and mortality in the world. The importance of developing advanced diagnostic, prognostic, and therapeutic monitoring tools cannot be overemphasized. Biomarkers have emerged as invaluable resources for tracking disease outcomes, assessing severity, and evaluating treatment efficacy. This review will explore the landscape of biomarkers for CAD, focusing on their role in providing precision medicine approaches for this complex condition. Biomarkers, such as Troponin I (TnI) and C-reactive protein (CRP), have been established in identifying myocardial damage and inflammation, respectively, which correlate with the severity of coronary atherosclerosis and high-risk plaque characteristics. In parallel, new biomarkers based on transcriptomics, such as circulating microRNAs (e.g., miR-126, miR-223, miR-19), may open new avenues for early detection and risk stratification. These RNA molecules are linked to the molecular basis of CAD, which is the connection between endothelial dysfunction and inflammatory cascades with adverse cardiovascular events. Quantitative imaging biomarkers include coronary artery calcium scores (CACS) and the features of high-risk plaque (HRP) found by coronary computed tomography angiography (CCTA). They provide a real-time assessment of the plaque burden and vulnerability. Increasing evidence is emerging with the incorporation of biomarker profiles and imaging tools for improved risk stratification and, consequently, individualized treatment pathways. Such biomarkers include Growth Differentiation Factor-15 (GDF-15) and soluble ST2, which are potential candidates for predicting the disease's progression and the response to pharmacological interventions. Recent advances in the omics technologies, namely genomics, proteomics, and metabolomics, have expanded the range of CAD biomarkers with the potential to identify patientspecific therapeutic targets. However, significant challenges remain in translating such discoveries into clinical practice because of variability in biomarker expression, lack of standardization, and large-scale validation studies.

Autoimmune disease is a condition in which the immune system mistakenly damages healthy cells in the human body. There are different types of autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren’s syndrome, Type-I diabetes, autoimmune hepatitis, multiple sclerosis (MS), myasthenia gravis, etc. Biomarkers are used to determine disability progression, monitor ongoing disease activity, and measure treatment response. Thus, these biomarkers are required to decide the therapy for the treatment of autoimmune diseases. Different types of biomarkers, such as diagnostic biomarkers, prognostic biomarkers, predictive biomarkers, monitoring biomarkers, emerging biomarkers, etc., are used in the diagnosis and treatment of different autoimmune diseases. The ideal biomarker can act as a diagnostic tool and monitoring method to determine the efficacy of therapeutic agents. This chapter encompasses the types of autoimmune diseases and the classification of biomarkers in autoimmune diseases. It also includes applications of biomarkers in autoimmune diseases, as well as challenges and future prospects in biomarker research for autoimmune diseases. Furthermore, the integration of biomarker-based strategies into clinical practice is explored, emphasizing their utility in improving therapeutic outcomes and reducing adverse effects. This review highlights the importance of biomarker research in advancing the understanding and management of autoimmune diseases.

Cardio-oncology is at the intersection of cardiology and oncology, focusing on an emerging dual mandate of optimizing outcomes in cancer therapies and minimizing associated cardiovascular toxicity. The cardiovascular consequences of cancer treatment include anthracyclines, trastuzumab, and checkpoint inhibitors, covering the spectrum of asymptomatic myocardial injury through overt heart failure and arrhythmias. These complications have a great impact on the quality of life and survival of cancer patients, and thus, early identification and proactive management are necessary. Robust serum biomarkers have become indispensable tools for risk stratification, early diagnosis, and therapeutic monitoring, providing a non-invasive and cost-effective approach to patient management. Traditional biomarkers, such as cardiac troponins and natriuretic peptides, remain the mainstay for detecting myocardial injury and cardiac dysfunction. Troponins are very sensitive and specific markers of acute and cumulative cardiotoxic effects of therapies. Natriuretic peptides, including B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP), are important for the diagnosis and monitoring of heart failure. However, these biomarkers are often unable to detect subclinical cardiotoxicity or to fully capture the complex pathophysiological mechanisms underlying cancer therapy-induced cardiac injury. In doing so, emergent biomarkers have expanded the horizon of cardio-oncology beyond the earlier simplistic diagnostic and prognostic limitations. Galectin-3 and soluble ST2, with their potential roles in fibrosis and myocardial stress, indicate early stages of cardiac remodeling. GDF-15, one of the related inflammation biomarkers, has become more useful in its ability to forecast adverse cardiovascular consequences in cancer patients undergoing cardiotoxic treatments. In addition, circulating microRNAs (miRNAs), small noncoding RNAs, have emerged as highly specific and sensitive indicators of myocardial stress and injury. Among these, miR-126, miR-208, and miR-34a are notably interesting as they play roles in detecting subclinical cardiotoxicity and provide insight into disease progression. Advances in proteomics, metabolomics, and multi-biomarker panel technologies have further helped to enhance serum biomarkers. High-throughput omics platforms also help in the discovery of previously uncharacterized biomarkers and clarify the molecular mechanisms of cardiotoxicity.

Highly heterogeneous and complex, cancer displays distinct molecular and cellular characteristics in various tumor types. Despite incredible achievements in oncology, there is currently no universal diagnostic or therapeutic target. Biomarkers represent biologically significant molecules that serve as indicators of a disease's presence, progression, or response to treatment, which are essential for early detection, prognosis, and precision therapy selection. An ideal biomarker should be adaptable, allowing its application in different types of cancers while maintaining specificity and sensitivity at the highest degree. This review will present the state of adaptable biomarkers and their relevance to unified strategies in diagnostic and treatment settings among various types of malignancies. Molecular pathways that have a high alteration frequency in cancer include the TP53, PI3K/AKT/mTOR, and RAS-RAF-MEK pathways, which offer a basis for adaptable biomarkers and therapeutic targets. These pathways serve critical roles in cell proliferation, survival, metabolism, and evasion of the immune response, making them candidates for broad-spectrum cancer therapeutics. In addition, newly established biomarkers of the TME, such as immune checkpoint proteins (PD-1, PD-L1, and CTLA-4), metabolic markers (LDH and glutaminase), and the stromal elements, have been identified as a part of tumour progression and response. Advances in liquid biopsy technology have further made it possible to detect circulating tumor DNA (ctDNA), exosomal microRNAs, and tumor-educated platelets, which enable real-time monitoring of disease dynamics and treatment efficacy. Despite the promise of adaptable biomarkers, several challenges persist, including tumor heterogeneity, resistance mechanisms, and economic barriers to widespread implementation. Addressing these challenges requires a multi-omics approach, integrating genomics, transcriptomics, proteomics, and metabolomics to refine biomarker-driven therapeutic strategies. In this review, a comprehensive account is given for the current scenario regarding adaptable biomarkers, therapeutic implications, and the potential directions ahead in personalized cancer care.

Biomarkers are used for diagnostic, prognostic, and predictive purposes. They play key roles in the diagnosis, progression, and management of diseases. The roles of biomarkers are as follows: diagnostic biomarkers help recognize precise diseases, such as troponin levels representing heart attacks, prognostic biomarkers offer insights into disease development or outcomes, like gene profiles predicting cancer survival, and predictive biomarkers forecast treatment responses, such as HER2 status guiding breast cancer therapy. Biomarkers are transforming modern medicine by facilitating personalized and targeted treatment approaches, enabling more precise, effective, and individualized therapeutic strategies. Biomarkers are measurable biological indicators, such as molecules, genes, or other markers of disease, that play a pivotal role in advancing healthcare by providing a deeper understanding of disease biology at the individual level. They are critical not only for diagnosing and predicting the progression of various conditions but also for guiding the selection of optimal treatments tailored to specific patient populations. The emergence of personalized medicine, which leverages individual biomarkers to create customized treatment plans, represents a groundbreaking shift in contemporary healthcare. This chapter delves into the significant roles of biomarkers in driving advancements in personalized and targeted therapies, with a particular focus on their utilization in oncology, cardiovascular diseases, and neurological disorders. Additionally, it highlights emerging trends and technologies in biomarker discovery, addresses challenges in clinical implementation, and explores future directions for this rapidly evolving field.